Compare · NVO vs THRN
NVO vs THRN
Side-by-side comparison of Novo Nordisk A/S (NVO) and Thorne Healthtech Inc. (THRN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and THRN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 714.0x THRN ($257.5M).
- NVO has hit the wire 5 times in the past 4 weeks while THRN has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 6 for THRN).
- Company
- Novo Nordisk A/S
- Thorne Healthtech Inc.
- Price
- $41.18+6.93%
- $10.20+0.00%
- Market cap
- $183.82B
- $257.5M
- 1M return
- +13.32%
- -
- 1Y return
- -34.24%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest THRN
- SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)
- SEC Form 15-12G filed by Thorne Healthtech Inc.
- Varma Saloni S. returned 581,643 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Mckenna Thomas P. returned 1,172,227 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Mccamy William C. returned 589,804 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Kauss Sarah M returned 105,874 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Jacobson Paul F returned 3,928,411 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Braglia Riccardo returned 5,424,550 shares to the company (SEC Form 4)
- Varma Saloni S. covered exercise/tax liability with 3,454 shares, decreasing direct ownership by 4% to 81,643 units (SEC Form 4) (Amendment)
- Mckenna Thomas P. covered exercise/tax liability with 11,257 shares, decreasing direct ownership by 1% to 795,740 units (SEC Form 4) (Amendment)